305 related articles for article (PubMed ID: 15530639)
1. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
[TBL] [Abstract][Full Text] [Related]
2. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
Vohora D
IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
[TBL] [Abstract][Full Text] [Related]
3. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
4. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
5. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
6. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
Onodera K; Watanabe T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
[TBL] [Abstract][Full Text] [Related]
7. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
8. Histamine H3 receptors and sleep-wake regulation.
Lin JS; Sergeeva OA; Haas HL
J Pharmacol Exp Ther; 2011 Jan; 336(1):17-23. PubMed ID: 20864502
[TBL] [Abstract][Full Text] [Related]
9. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
10. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
Chazot PL; Hann V
Curr Opin Investig Drugs; 2001 Oct; 2(10):1428-31. PubMed ID: 11890359
[No Abstract] [Full Text] [Related]
11. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
Witkin JM; Nelson DL
Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
[TBL] [Abstract][Full Text] [Related]
12. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
13. Histamine H3 receptor as a drug discovery target.
Berlin M; Boyce CW; Ruiz Mde L
J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
[No Abstract] [Full Text] [Related]
14. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of histamine H3 receptor agonists and antagonists.
Leurs R; Blandina P; Tedford C; Timmerman H
Trends Pharmacol Sci; 1998 May; 19(5):177-83. PubMed ID: 9652190
[TBL] [Abstract][Full Text] [Related]
16. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers.
Schnell D; Burleigh K; Trick J; Seifert R
J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746
[TBL] [Abstract][Full Text] [Related]
17. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
Leurs R; Bakker RA; Timmerman H; de Esch IJ
Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
[TBL] [Abstract][Full Text] [Related]
18. [The histamine H3 receptor: a new target for the treatment of arousal and cognitive disorders].
Arrang JM
Ann Pharm Fr; 2007 Jul; 65(4):275-84. PubMed ID: 17652997
[TBL] [Abstract][Full Text] [Related]
19. [The histaminergic system: a target for innovative treatments of cognitive deficits].
Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
[TBL] [Abstract][Full Text] [Related]
20. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]